The investment activity around Quest Diagnostics Incorporated (DGX) has seen substantial movement. Large investment groups, including Galvin Gaustad & Stein, Bar Harbor Wealth Management, and Vontobel Holding Ltd. have recently adjusted their stake in the company. Additionally, financial advising firms such as Evercore ISI Group and Baird have increased their target price for the stock. Analysts remain optimistic towards the company, with Weiss Ratings reaffirming a buy rating. A transformative development is the company's Shield Partnership aiming to shift the role Quest Diagnostics plays in preventive health innovation. Notably, Quest Diagnostics has also partnered with Google Cloud to innovate using generative AI. Another strategic move comes in the form of a joint venture with Corewell Health to boost laboratory services in Michigan. On the product front, Quest Diagnostics pioneered testing for the Oropouche Virus, introducing new AD-Detect™ Blood Test for Alzheimer's diagnosis and has developed a Multi-cancer Stratification (MCaST) Blood Test. The company's financial health looks promising with Q2 2025 earnings surpassing estimates and a proposed 6.7% quarterly dividend increase.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Sat, 11 Oct 2025 10:54:29 GMT - Rating 8 - Innovation 4 - Information 9 - Rumor -3
